Avrobio cancels Fabry disease gene therapy research programme following poor results
Despite earlier promising results, AVROBIO cancelled its FD therapy AVR-RD-01 following poor results from its Phase II clinical trial.
By
GlobalData Healthcare
Latest articles
All Articles
Twitter roundup: top five neurology tweets in Q3
Clinical Trial Arena lists five of the most popular tweets on neurology in Q3 2021 based on data from…
NewAmsterdam Pharma initiates Phase III trial for obicetrapib
NewAmsterdam Pharma has announced dose administration for the first patient in its Phase III BROADWAY trial for its lead…
By
National Thyroid Awareness Month shines a spotlight on disorders like hypothyroidism
Increasing awareness of hypothyroidism and other thyroid disorders represents an important public health strategy.
By
The changing dynamics of gene therapy research: 2001–2021
According to the analysis, there has been an increase in gene therapy clinical trials during these 20 years, with…
By
Unmet needs in DMD will be partially met by the pipeline
Trends imply that there is still ample space for novel products to enter the market.
By
Armgo Pharma secures $35 million to advance rare heart disease drug to phase II
CPVT is a rare, life-threatening disease predominately caused by mutations in ryanodine receptor 2 (RyR2), the major Ca2+ release…
By
CDC recommends doctors talk to all sexually active people about HIV prevention
People at risk for HIV can take pre-exposure prophylaxis (PrEP) to prevent getting HIV from sex or injection drug…
By
Encouraging pipeline for patients with Fragile X Syndrome
FXS is the leading cause of inherited intellectual disability and autism spectrum disorder.
By